These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 28408486)

  • 1. Targeting ROR1 identifies new treatment strategies in hematological cancers.
    Karvonen H; Niininen W; Murumägi A; Ungureanu D
    Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Wnt signaling pseudokinases in hematological cancers.
    Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
    Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.
    Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
    Leuk Lymphoma; 2013 Apr; 54(4):843-50. PubMed ID: 22988987
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.
    Choi MY; Widhopf GF; Ghia EM; Kidwell RL; Hasan MK; Yu J; Rassenti LZ; Chen L; Chen Y; Pittman E; Pu M; Messer K; Prussak CE; Castro JE; Jamieson C; Kipps TJ
    Cell Stem Cell; 2018 Jun; 22(6):951-959.e3. PubMed ID: 29859176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy.
    Shabani M; Naseri J; Shokri F
    Expert Opin Ther Targets; 2015 Jul; 19(7):941-55. PubMed ID: 25835638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.
    Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
    Semin Cancer Biol; 2014 Dec; 29():21-31. PubMed ID: 25068995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
    Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
    Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
    Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.
    Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
    Cell Death Dis; 2021 Jun; 12(6):577. PubMed ID: 34088900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.
    Dave H; Anver MR; Butcher DO; Brown P; Khan J; Wayne AS; Baskar S; Rader C
    PLoS One; 2012; 7(12):e52655. PubMed ID: 23285131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
    Karvonen H; Chiron D; Niininen W; Ek S; Jerkeman M; Moradi E; Nykter M; Heckman CA; Kallioniemi O; Murumägi A; Ungureanu D
    Blood Adv; 2017 Nov; 1(24):2257-2268. PubMed ID: 29296874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
    Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE
    Gynecol Oncol; 2018 Mar; 148(3):576-584. PubMed ID: 29395309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
    Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
    J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
    Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
    J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
    Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
    PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
    J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL.
    Chow M; Gao L; MacManiman JD; Bicocca VT; Chang BH; Alumkal JJ; Tyner JW
    Oncogene; 2018 Sep; 37(38):5221-5232. PubMed ID: 29849118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
    Zhang S; Zhang H; Ghia EM; Huang J; Wu L; Zhang J; Lam S; Lei Y; He J; Cui B; Widhopf GF; Yu J; Schwab R; Messer K; Jiang W; Parker BA; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1370-1377. PubMed ID: 30622177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target.
    Heliste J; Jokilammi A; Paatero I; Chakroborty D; Stark C; Savunen T; Laaksonen M; Elenius K
    BMC Cardiovasc Disord; 2018 Oct; 18(1):196. PubMed ID: 30342492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.